A phase 1/2 trial (NCT04892017) found a potential treatment with DCC-3116 monotherapy given between 50 mg to 300 mg twice daily for patients with RAS or RAF-mutant solid tumors, based on a presentation from the 2022 European Society for Medical Oncology Congress. At the June 9, 2022, data cutoff, no dose-limiting toxicities or serious treatment-emergent adverse effects (TEAEs) were reported. Additionally, …
Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board
CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has formed a Scientific Advisory Board (SAB) in support of the development of its lead therapeutic candidate QN-302 for the …
Valentina Boni, MD, PhD, Talks Safety of Lurbinectedin Monotherapy in Pretreated BRCA-Associated Advanced Breast Cancer
Valentina Boni, MD, PhD, of the Early Drug Development Unit at the Universitary Hospital Universitario Quirónsalud Madrid as well as director and principal investigator at NEXT Oncology Madrid in Spain, spoke with CancerNetwork® at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about lurbinectedin (Zepzelca) monotherapy for patients with BRCA1/2-associated metastatic breast cancer, which was examined in a phase 2 basket study …
SA cancer research group ramping up Spain expansion
San Antonio has a deep bench and long history in cancer research, and it’s expanding on that expertise and infrastructure on multiple fronts, drawing more talent and investment to back that growth. This spring, San Antonio-based NEXT Oncology launched operations in Spain with an early-phase clinical trial in Madrid. It’s part of a growth plan founder Dr. Anthony Tolcher outlined …
Virginia Cancer Patient “Living with (Stage 4) Cancer” Thanks to Clinical Trial
Dr. Alexander I. Spira presented promising research findings at The American Societyof Clinical Oncology (ASCO) to help those with lung cancer. (FAIRFAX, VIRGINIA) June 27, 2022 –– Chuck Tonkin, 82, has been battling cancer since 2018. Now with stage 4 lung cancer, with metastatic disease to his brain, has found a new drug, adagrasib, that is giving him his life …
NEXT Oncology Gives Patient Her Life Back with Clinical Trials
P53, guardian of the genome, prevents solid tumor growth (SAN ANTONIO) June 10, 2022 –– Lindalou Trevino was the first patient to enroll in clinical trial PC14586, and because of her favorable response to this new investigational drug, she has renewed hope and a new lease on life. PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective …
PMV’s ASCO data show signs of drugging ‘undruggable’ p53 protein across tumor types
PMV Pharmaceuticals has its first clinical data showing that its lead therapeutic candidate can hit p53, a tumor-suppressing protein long thought to be undruggable. After reporting the preliminary data during ASCO, PMV said it plans to continue the Phase 1 study with the goal of advancing to Phase 2 early next year. The tumor-suppressing protein p53 has long been considered …
Adagrasib Shows Promise in Difficult-to-Treat Lung Cancer Subset
When given as a single-agent (not with any other drugs), adagrasib led to promising outcomes for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to results from part of the phase 1/2 KRYSTAL-1 clinical trial that were presented at the 2022 American Society of Clinical Oncology Annual Meeting. At the meeting, Dr. Alexander I. Spira, co-director of Virginia Cancer …
NEXT Oncology Enrolls First Patient in Madrid Phase I Clinical Research Center
When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer (TNBC) with an anti-drug conjugate used in …
NEXT Oncology Enrolls First Patient in Madrid Phase I Clinical Research Center
New trial clinical trial is focused on novel therapy for triple negative breast cancer. (SAN ANTONIO) April 14, 2022 –– When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 …